Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT06353477

Hand, Foot, and Mouth Disease: Could EPs®7630 be a Treatment Option

Use of EPs®7630 in Hand, Foot and Mouth Disease

Sponsor: Abdi Ibrahim Ilac San. ve Tic A.S.

Conditions Hand, Foot, and Mouth Disease

Interventions EPs® 7630

Updated 4 times since 2024 Last updated: Apr 2, 2024 Started: Jun 1, 2019 Primary completion: Jun 1, 2022 Completion: Jan 1, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06353477, this PHASE2/PHASE3 trial focuses on Hand, Foot, and Mouth Disease and remains completed. Sponsored by Abdi Ibrahim Ilac San. ve Tic A.S., it has been updated 4 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2/PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
May 2024 — Jul 2024 [monthly]

Completed PHASE2_PHASE3

First recorded

Jun 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abdi Ibrahim Ilac San. ve Tic A.S.
Eskisehir Osmangazi University

Data source: Eskisehir Osmangazi University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Esenyurt, Turkey (Türkiye)